Side-by-side comparison of AI visibility scores, market position, and capabilities
Nation's largest clinical lab with 230M tests/year; $9.8B FY2024 revenue; liquid biopsy and genomic oncology testing growth; consumer-direct app strategy; competes with Labcorp.
Quest Diagnostics is the nation's leading provider of diagnostic information services, founded in 1967 as MetPath and headquartered in Secaucus, New Jersey, trading on NYSE (DGX). The company processes approximately 230 million clinical laboratory tests annually, serving patients through approximately 2,250 patient service centers, physician offices, hospitals, and health plans across the United States. For FY2024, Quest generated approximately $9.8 billion in total revenues under CEO James Davis, who succeeded Steve Rusckowski in 2022 and has accelerated the company's strategy of expanding consumer access, digital connectivity with ordering physicians, and advanced specialty testing capabilities in oncology, genetics, and infectious disease.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.